ML379 (CID71576758) is a potent, selective TP53 mutant cancer cells inhibitor with IC50 of 13 nM in sensitive HeLa cells (TP53 mutant).

ML378 (CID71710938, JJH-254) is an in vivo active carbamate-based dual inhibitor of lysophospholipase LYPLA1 (APT1) and LYPLA2 (APT2) with IC50 of 122 nM and 245 nM, repectively.

ML377 (MLS 0472732) is a small molecule probe that selectively inhibits TAG (Triacylglyceride) accumulation with an IC50 of 1.1 uM, show >45-fold selectivity versus DGAT inhibition and cytotoxicity..

ML375 (VU-0483253) is a potent, highly selective M5 NAM with submicromolar potency (human M5 IC50=300 nM, rat M5 IC50=790 nM, M1-M4 IC50> 30 uM), exhibts excellent multispecies PK, high CNS penetration, and enantiospecific inhibition..

ML368 (SR 9186) is a potent, selective cytochrome P450 enzyme CYP3A4 inhibitor with IC50 of 4 nM (convert testosterone to hydroxytestosterone), displays >2,000-fold selectivity over CYP3A5..

ML358 is a first in class, selective small molecule inhibitor of the SKN-1 pathway with IC50 of 0.24 uM.

ML352 (VU-0476201) is a potent, selective choline transporter (CHT) inhibitor with Ki of 92 nM.

ML350 (CYM 50202) is a highly potent and selective Opioid kappa receptor (OPRK1/KOR) antagonist with IC50 of 9-16 nM.

ML-290 is a potent and orally active relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM.

ML279 is a potent and reversible inhibitor of lipid uptake via SR-BI (scavenger receptor BI) with IC50 of 17 nM.

ML197 is a potent, selective small molecule inhibitor of Cdc2-like kinases (CLK) and DYRK with IC50 of 96/40/206 nM for CLK1/CLK4/Dyrk1A, respectively.

ML-184 (ML184) is a potent, selective GPR55 agonist with EC50 of 263 nM, >120-fold, 83-fold, and 57-fold selectivity against GPR35, CB1 and CB2.

ML133 (CID781301) is a potent, selective K(ir)2.1 potassium channel with IC50 of 1.8 uM at pH 7.4 and 290 nM at pH 8.5, respectively.

ML133 (CID781301) is a potent, selective K(ir)2.1 potassium channel with IC50 of 1.8 uM at pH 7.4 and 290 nM at pH 8.5, respectively.

ML132 (NCGC-00183434, CID-4462093) is a highly potent, selective Caspase 1 inhibitor with IC50 of 0.023 nM, displays >1,000-fold selectivity over a panel of 9 caspases..

ML119 (CID1357397.

ML115 is a novel "bone-seeking" bisphosphonate based MMP-2 specific inhibitor (BMMPI), spares the activity of other MMPs including MMP-9.

ML104 is a novel "bone-seeking" bisphosphonate based MMP-2 specific inhibitor (BMMPI), spares the activity of other MMPs including MMP-9.

ML00253764 is a non-peptide, brain penetrant melanocortin MC4 receptor (MC4R) antagonist with IC50 of 0.32, 0.81 and 2.12 uM for MC4, MC3 and MC5 receptors, respectively.

ML00253764 is a non-peptide, brain penetrant melanocortin MC4 receptor (MC4R) antagonist with IC50 of 0.32, 0.81 and 2.12 uM for MC4, MC3 and MC5 receptors, respectively.

ML 604440 (ML604440, ML-604440) is a potent, specific and cell permeable proteasome β1i (LMP2) subunit inhibitor.

ML 604086 (ML604086) is a potent, selective CCR8 inhibitor that inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+ concentrations with IC50 of 1.3 uM and 1.0 uM respectively in cellular assays.

ML 309 is a potent, selective mutant IDH1 R132H inhibitor with IC50 of 96 nM.

ML 309 is a potent, selective mutant IDH1 R132H inhibitor with IC50 of 96 nM.

MKK7-COV-9 (MKK7 Covalen inhibitor 9) is a potent, selective, covalent MKK7 inhibitor, displays >1,000-fold selectivity over MKK4.

MKK7-COV-13 (MKK7 Covalen inhibitor 13) is a potent, selective, covalent MKK7 inhibitor with in vitro IC50 of 10 nM, displays >1,000-fold selectivity over MKK4 (IC50>10 uM).

MKC9989 is a specific small molecule inhibitor of IRE1α Rnase (Kd=0.84 uM) with potency against the splicing of XBP1 mRNA (EC50=0.33 uM)..

MK-9470 is a potent, selective cannabinoid CB1 receptor (CB1R) inverse agonist with IC50 of 0.7 nM, 18F MK-9470 has been developed for use in human brain imaging..

MK-886 is an inhibitor of leukotriene biosynthesis (IC50 = 3 nM in human polymorphonuclear leukocytes).

MK-8825 is a highly potent, selective, orally bioavailable CGRP receptor antagonist with Ki of 17 nM for rat CGRP.